Clinical trials: T-Cell Non-Hodgkin Lymphoma
Anaplastic Large Cell Lymphoma, Recurrent Childhood Anaplastic Large Cell Lymphoma
Ifosfamide, Carboplatin, Etoposide, and SGN-30 in Treating Young Patients With Recurrent Anaplastic Large Cell Lymphoma
This phase I/II trial is studying the side effects and best dose of SGN-30 when given together with ifosfamide, carboplatin, and etoposide and to see how well they work in treating young patients with recurrent anaplastic large…
- Trial name
- NCT00354107
- Testing
- monoclonal antibody SGN-30, therapeutic hydrocortisone, ifosfamide
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- National Cancer Institute (NCI)
NK/T-Cell Lymphoma of Nasal Cavity (Diagnosis), NK/T-Cell Lymphoma of Nasopharynx (Diagnosis)
Study of Pembrolizumab in Patients With Early-Stage NK/T-cell Lymphoma, Nasal Type
The purpose of this study is to test how well pembrolizumab shrinks Early-Stage NK/T-cell Lymphoma (ENKTL) in participants who have not yet received chemotherapy.
- Trial name
- NCT03728972
- Testing
- Pembrolizumab
- Where
- 10 sites in United States
- Volunteers
- 19 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
T-cell Acute Lymphoblastic Leukemia, T-cell Lymphoma
Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)
This is a clinical trial testing whether the addition of one of two chemotherapy agents, dasatinib or venetoclax, can improve outcomes for children and young adults with newly diagnosed T-cell acute lymphoblastic leukemia and…
- Conditions
- T-cell Acute Lymphoblastic Leukemia, T-cell Lymphoma, Mixed Phenotype Acute Leukemia
- Trial name
- NCT06390319
- Testing
- Dexamethasone, Vincristine, Daunorubicin
- Where
- 4 sites in United States
- Volunteers
- 100 people
- Sponsor
- St. Jude Children's Research Hospital
Acute Leukemia of Ambiguous Lineage, B Acute Lymphoblastic Leukemia
Testing Blinatumomab With or Without Revumenib in Patients With B-cell Acute Lymphoblastic Leukemia With a Genetic Change Requiring More Treatment
This phase II trial tests how well adding revumenib to usual treatment (blinatumomab) compared to usual treatment alone works in treating patients with B-cell acute lymphoblastic leukemia (B-ALL) or acute leukemia with ambiguous…
- Conditions
- Acute Leukemia of Ambiguous Lineage, B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative, T Acute Lymphoblastic Leukemia
- Trial name
- NCT07636564
- Testing
- Biospecimen Collection, Blinatumomab, Bone Marrow Aspiration
- Volunteers
- 90 people
- Sponsor
- SWOG Cancer Research Network
Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia
Programmed Allogeneic CRISPR-edited T Cells Engineered to Express Anti-CD19 Chimeric Antigen Receptor (PACE CART19) in Patients With Relapsed Or Refractory CD19+ Leukemia and Lymphoma
This is a Phase I trial to assess the safety and feasibility of administering pre-manufactured allogeneic T cells from healthy donors expressing CD19-targeting chimeric antigen receptors lacking expression of HLA class I, HLA…
- Conditions
- Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia, Non Hodgkin Lymphoma
- Trial name
- NCT05037669
- Testing
- PACE CART19
- Sponsor
- University of Pennsylvania
Leukemia, Lymphoma
Chemotherapy Given With Amifostine and Filgrastim in Treating Patients With Recurrent or Metastatic Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Chemoprotective drugs such as amifostine may protect normal cells from the side effects of chemotherapy.
- Conditions
- Leukemia, Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00003294
- Testing
- filgrastim, amifostine trihydrate, carboplatin
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Roswell Park Cancer Institute
Leukemia, Lymphoma, Non-Hodgkin
Infusion of Genetically Modified T Cell for Post Transplant Patients With Relapsed Disease
Primary Objective: To determine if there is significant toxicity associated with the administration of CD34-TK75 transduced donor lymphocytes after allogeneic BMT for relapsed hematologic malignancies Secondary Objectives: To…
- Conditions
- Leukemia, Lymphoma, Non-Hodgkin, Hodgkin Disease, Myelodysplastic Syndromes
- Trial name
- NCT00871702
- Testing
- CD34-TK75 transduced donor lymphocytes, Sub Study - 18 FHBG PET/CT Scans
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Washington University School of Medicine
Lymphoma, T-Cell, Cutaneous
A Study of the Histone Deacetylase Inhibitor (HDACi) Quisinostat (JNJ-26481585) in Patients With Previously Treated Stage Ib-IVa Cutaneous T-cell Lymphoma
The purpose of this study is to determine the overall cutaneous response rate (participants who achieve a complete response or partial response) based on the modified severity weighted assessment tool criteria.
- Trial name
- NCT01486277
- Testing
- Quisinostat, 12 mg
- Where
- 13 sites in United States, France and 4 more
- Volunteers
- 26 people
- Sponsor
- Janssen Research & Development, LLC
Peripheral T-cell Lymphoma
A Phase 1 Study of SP-02L in Relapsed or Refractory Patients With Peripheral T-cell Lymphoma (PTCL)
The purpose of this study is to evaluate the safety and tolerability of SP-02L monotherapy in Japanese patients with relapsed or refractory Peripheral T-cell Lymphoma (PTCL).
- Trial name
- NCT01435863
- Testing
- SP-02L (darinaparsin for injection)
- Where
- 4 sites in Japan
- Volunteers
- 17 people
- Sponsor
- Solasia Pharma K.K.
Hematopoietic/Lymphoid Cancer, Adult Acute Lymphoblastic Leukemia in Remission
Genetically Engineered Lymphocyte Therapy in Treating Patients With Lymphoma That is Resistant or Refractory to Chemotherapy
RATIONALE: Placing a gene that has been created in the laboratory into white blood cells may make the body build an immune response to kill cancer cells.
- Conditions
- Hematopoietic/Lymphoid Cancer, Adult Acute Lymphoblastic Leukemia in Remission, B-cell Adult Acute Lymphoblastic Leukemia, B-cell Chronic Lymphocytic Leukemia
- Trial name
- NCT01735604
- Testing
- anti-CD20-CAR vector-transduced autologous T cells, genetically engineered lymphocyte therapy
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Chinese PLA General Hospital
Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma
Clinical Study of XPO-1 Inhibitors Plus CAR-T Cells in Relapsed Refractory B-cell Non-Hodgkin's Lymphoma
Aim of this study will evaluate the Efficacy and Safety of XPO-1 inhibitors in combination with CAR-T cells in relapsed refractory B-cell non-Hodgkin's lymphoma
- Trial name
- NCT05322330
- Testing
- Selinexor, Flu, CTX
- Where
- China
- Volunteers
- 20 people
- Sponsor
- The First Affiliated Hospital of Soochow University
NHL, DLBCL - Diffuse Large B Cell Lymphoma
Comparison of Point-of-care Produced CAR T-cell With Commercial CAR T-cells in Patients With R/R LBCL
A phase II, multi-center study to compare the feasibility, and clinical efficacy of local manufacturing of CD19-directed CAR T-cells (ARI-0001 CAR T-cells) with commercial produced CAR T-cells (for example axicabtagene…
- Trial name
- HOVON161 (NCT05641428)
- Testing
- ARI-0001, Axi-cel
- Where
- 7 sites in Netherlands
- Volunteers
- 340 people
- Sponsor
- University Medical Center Groningen
Anaplastic Large Cell Lymphoma, ALK-Positive, Ann Arbor Stage II Noncutaneous Childhood Anaplastic Large Cell Lymphoma
Brentuximab Vedotin or Crizotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II-IV Anaplastic Large Cell Lymphoma
This partially randomized phase II trial studies how well brentuximab vedotin or crizotinib and combination chemotherapy works in treating patients with newly diagnosed stage II-IV anaplastic large cell lymphoma.
- Conditions
- Anaplastic Large Cell Lymphoma, ALK-Positive, Ann Arbor Stage II Noncutaneous Childhood Anaplastic Large Cell Lymphoma, Ann Arbor Stage III Noncutaneous Childhood Anaplastic Large Cell Lymphoma, Ann Arbor Stage IV Noncutaneous Childhood Anaplastic Large Cell Lymphoma
- Trial name
- NCT01979536
- Testing
- Brentuximab Vedotin, Crizotinib, Cyclophosphamide
- Where
- 154 sites in United States
- Volunteers
- 137 people
- Sponsor
- National Cancer Institute (NCI)
Recurrent Chronic Lymphocytic Leukemia, Recurrent Diffuse Large B-Cell Lymphoma
Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies
This phase II trial studies how well nivolumab works for the treatment of hematological malignancies that have come back (relapsed), does not respond (refractory), or is detectable after CAR T cell therapy.
- Conditions
- Recurrent Chronic Lymphocytic Leukemia, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Follicular Lymphoma, Recurrent Grade 1 Follicular Lymphoma
- Trial name
- NCT04205409
- Testing
- Nivolumab
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Washington
B-Cell Lymphoma, Large B-cell Lymphoma
Study of 19(T2)28z1xx TRAC-Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Lymphoma
The purpose of this research is to evaluate if study therapy, 19(T2)28z1xx TRAC-chimeric antigen receptor (CAR) T cells, may be an effective treatment for people with relapsed/refractory B-cell lymphoma.
- Conditions
- B-Cell Lymphoma, Large B-cell Lymphoma, DLBCL, Nos Genetic Subtypes, High-grade B Cell Lymphoma
- Trial name
- NCT05757700
- Testing
- 19(T2)28z1xx TRAC T cell
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Diffuse Large B Cell Lymphoma (DLBCL)
Pixantrone as Bridging Therapy to Allogenic Transplant or CAR-T Cell Therapy in DLBCL Patients
Retrospective/prospective observational multicentric study aimed at describing the effectiveness of pixantrone as bridging therapy to allo-HSCT or CAR-T therapy
- Trial name
- PIXBRIDGE (NCT06760936)
- Where
- Italy
- Volunteers
- 15 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Cutaneous T-cell Lymphoma
Phase I/II Study of Linperlisib Plus Chidamide for R/R Cutaneous T-cell Lymphoma: a Prospective, Single-center Study
HDAC inhibitor chidamide and PI3K inhibitor linperlisib has shown clinical activity as mono therapy in PTCL. The combination of duvelisib and romidepsin is highly active against relapsed and refractory T-cell lymphomas including…
- Trial name
- NCT06037239
- Testing
- Linperlisib in combined with Chidamide
- Where
- China
- Volunteers
- 53 people
- Sponsor
- Peking Union Medical College Hospital
Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
BAFFR-targeting CAR T Cells for Patients With Relapsed or Refractory B-NHL
A Phase 1 Study Evaluating BAFFR-targeting CAR T Cells for Patients with Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma (B-NHL)
- Trial name
- NCT05370430
- Testing
- BAFFR-CAR T cells
- Where
- 6 sites in United States
- Volunteers
- 36 people
- Sponsor
- PeproMene Bio, Inc.
Mycosis Fungoides and Sézary Syndrome
Real World Observational Study of Poteligeo in Adult Patients With MF and SS (PROSPER)
This is a prospective, observational, non-interventional, international, multi-center, mixed methods study that will involve the integration of quantitative and qualitative data in patients with MF/SS treated with Poteligeo.
- Trial name
- PROSPER (NCT05455931)
- Testing
- Poteligeo
- Where
- 19 sites in United States, Italy and 4 more
- Volunteers
- 73 people
- Sponsor
- Kyowa Kirin Pharmaceutical Development Ltd
Peripheral T-Cell Lymphoma, Not Otherwise Specified, Angioimmunoblastic T Cell Lymphoma
CEOP/IVE/GDP Compared With CEOP as the First-line Therapy for Newly Diagnosed Adult Patients With PTCL
Peripheral T-cell Lymphoma (PTCL) is a heterogenic malignancy with poor outcome. Five-year PFS and OS for these patients received classic CHOP regimen (cyclophosphamide, vincristin, doxorubicin and prednisone) is less than…
- Conditions
- Peripheral T-Cell Lymphoma, Not Otherwise Specified, Angioimmunoblastic T Cell Lymphoma, ALK-negative Anaplastic Large Cell Lymphoma, Enteropathy Associated T Cell Lymphoma
- Trial name
- NCT02533700
- Testing
- CEOP/IVE/GDP chemotherapy regimen, CEOP chemotherapy regimen for 6 cycles
- Where
- 4 sites in China
- Volunteers
- 106 people
- Sponsor
- Shandong Provincial Hospital